Navigation Links
MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products

Spanish Public-private Foundation for Life Sciences Research Adopts the Genedata Screener® 7.0 Data Management Platform for High Throughput and High Content Screening.

Basel, Switzerland and Granada, Spain (PRWEB) December 8, 2009 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, and Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía), today announced their collaboration in the discovery of innovative medical compounds to fight infectious diseases, cancer and immune disorders. MEDINA has licensed the Genedata Screener platform - including the modules Condoseo for dose-response curve fitting and Kinetics Analyzer for the capture of time series data - for rapid and flexible data processing, management and analysis for all of their natural product screening and lead evaluation services. Those services span a wide range of assay technologies and instrumentation, from single-plate measurements to large-scale screens.

Fundación MEDINA has emerged from the Merck Sharp and Dohme (MSD) Basic Research Center in Madrid and houses comprehensive microbial collections and natural products libraries as well as a compound profiling platform for the identification of potential risks in cardiovascular safety and drug-drug interactions. Consequently, the MEDINA research teams need to master a multitude of screening technologies and set-up modifications on a daily basis, from anti-infective or biochemical inhibition assays to dose-response assay panels for the determination of potential compound risks.

"We received a clear vote from our users to go with Genedata," said Francisco Asensio, IT manager at Fundacion MEDINA. "The Screener system is unrivaled when it comes to the flexible and efficient integration of third-party infrastructure, and the easy templating for our complex assay setups impresses our screening teams just as much as it smoothes things out for our IT support people. As we inherited a large and disparate instrument park and built our entire organization from scratch, the need to align different technologies and research groups was a top priority."

"We are proud of our relationship with MEDINA," said Dr. Othmar Pfannes, CEO of Genedata. "Screener is an exceptional product thanks to its ability to master the breadth and complexity of today's screening scenarios. Introducing this product to the thriving Spanish life science market and establishing our presence there is an exciting challenge for Genedata. We are looking forward to a dynamic partnership with Fundación MEDINA and growing our business in Spain."

About Fundación MEDINA
Created in November 2008, Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía) is a non-profit public-private partnership between Merck Sharp and Dohme de Espana S.A. (MSD), the Junta de Andalucia and the University of Granada, Spain. MEDINA focuses on 1) the discovery of innovative compounds from microbial natural products to be licensed as new leads for development by industrial companies, and 2) ADME/TOX high throughput screening platform service for the evaluation of drug candidates.

About Genedata:
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, and Genedata Expressionist® make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Scientists demonstrate multibeam, multi-functional lasers
2. Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva
3. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
4. Scientists develop novel method to generate functional hepatocytes for drug testing
5. Harvard scientists bend nanowires into 2-D and 3-D structures
6. Scientists use math modeling to predict unknown biological mechanism of regulation
7. Weed Scientists Take Steps to Protect Rare Orchid
8. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
9. Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers
10. UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year
11. NIST scientists study how to stack the deck for organic solar power
Post Your Comments:
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
Breaking Biology News(10 mins):